Key result
This review discusses the clinical implications of active metabolites of Angiotensin II AT1 receptor antagonists.
Answers are grounded in this paper and cite their sources.
Active metabolites may refine ARB selection; leaves open their outcome impact pending prospective data.
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTAngiotensin II AT1 Receptor Antagonists. Clinical Implications of Active MetabolitesBoris Schmidt and Bernhard SchiefferView Author Information Clemens Schöpf Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Petersenstrasse 22, D-64287 Darmstadt, Germany, and Department of Cardiology and Angiology, Medizinische Hochschule Hannover, Hannover, Germany Cite this: J. Med. Chem. 2003, 46, 12, 2261–2270Publication Date (Web):May 8, 2003Publication History Received25 September 2002Published online8 May 2003Published inissue 1 June 2003https://pubs.acs.org/doi/10.1021/jm0204237https://doi.org/10.1021/jm0204237review-articleACS PublicationsCopyright © 2003 American Chemical SocietyRequest reuse permissionsArticle Views1807Altmetric-Citations101LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstract
No takes yet. Share an insight, caveat, or question.
Schmidt et al. (2003) reported a review. Angiotensin II AT1 Receptor Antagonists was evaluated. This review discusses the clinical implications of active metabolites of Angiotensin II AT1 receptor antagonists.
Synapse has enriched 10 related papers. Consider them for comparative context: